Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin-assisted psychotherapy for persistent post-concussion symptoms
ACTRN12626000576325Phase 2Not yet recruiting
- Sponsor
- Monash University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in Post-concussion syndrome (PCS) and traumatic brain injury (TBI) (2 arms), sponsored by Monash University. Primary endpoint: Persistent post-concussion symptoms. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
psilocybin
03
Conditions
Post-concussion syndrome (PCS)traumatic brain injury (TBI)
Beyond the preview
Go deeper on ACTRN12626000576325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000576325.